With nearly 50 years of cutting-edge experience in respiratory disease research, Zhong Nanshan’s respiratory disease prevention and control innovation team, led by Zhong Nanshan, He Jianxing and Ran Pixin, won the 2020 National Science and Technology Progress Award Innovation Team Award, ranging from “SARS” to “New Crown”, from lung cancer When it comes to COPD, their scientific attitudes and research results of seeking truth from facts, daring to speak up, and the supremacy of life have not only saved countless lives in China, but also played a pivotal role in the global prevention and treatment of respiratory diseases.
Zhong Nanshan’s respiratory disease prevention and control innovation team is the first team in the “SARS” to identify the pathogen and achieve the world’s highest treatment rate. It also plays an important role in the prevention and control of severe respiratory infectious diseases such as “Human Avian Influenza” and “Middle East Respiratory Syndrome” . And when the global outbreak of new crown pneumonia in 2020, the team members headed by Zhong Nanshan are a solid fortress to protect the health of the people. Seven national platforms, including the National Respiratory Medicine Center and the National Respiratory Diseases Clinical Medicine Research Center, have been built by the team to help China play a leading role in the global fight against the “new crown” epidemic.
Yang Zifeng, a researcher at the State Key Laboratory of Respiratory Diseases at the First Affiliated Hospital of Guangzhou Medical University: Last year, our team took the lead in uniting researchers from across the country to summarize (analyze), making us the first in the world to publish the clinical characteristics of the new crown (patient). This article is also one of the most frequently cited articles, indicating that our work experience in China (respiratory diseases) has guided the world’s work understanding of “anti-epidemic”.
After half a century, the Zhong Nanshan Respiratory Disease Prevention and Control Innovation Team has put forward new international concepts such as “occult asthma”, “no tube surgery”, “chronic obstructive lung early intervention and comprehensive prevention and control”, and has established an internationally leading assessment of lung cancer. The molecular marker prediction model of recurrence and the community model of early intervention and comprehensive prevention and control of COPD have made important contributions to the prevention, control, diagnosis and treatment and prognosis of respiratory diseases in my country.
Zhong Nanshan’s team believes that “early detection, early diagnosis, early detection, and early treatment” are the key to overcome major and chronic respiratory diseases. Taking lung cancer as an example, the team can diagnose and treat through timely screening, and the 5-year survival rate after surgery can reach 90% above.
Liang Wenhua, Deputy Chief Physician of the Department of Thoracic Oncology, First Affiliated Hospital of Guangzhou Medical University: In the past, early lung cancer was very difficult to diagnose. If people judge alone, the accuracy rate may be about 60%~70% nationwide. By joining us The (ctDNA detection) method can be increased to 90% (above).
From treating diseases and saving people to promoting cross-industry integration and development, Zhong Nanshan’s respiratory disease prevention and control innovation team has established a respiratory disease science popularization base and industry-university-research transformation center. The team keeps a close eye on international cutting-edge concepts and technologies in areas that are urgently needed by the country for disease prevention and control, and at the same time develops disease prevention, diagnosis and treatment methods and drugs suitable for national conditions. They have also promoted the construction and development of my country’s emergency response mechanism for public health emergencies, and promoted the development of a global public health crisis response system for respiratory infectious diseases.
Liang Wenhua, deputy chief physician of the Thoracic Oncology Department of the First Affiliated Hospital of Guangzhou Medical University: Because of these technological breakthroughs, we will have more and more exchanges with international counterparts. Every year, many doctors from developed countries in Europe and the United States will come to our center to study. Minimally invasive surgery without tube.